Andrea Tuettenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Tuettenberg has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Helmut Jonuleit
Department of Dermatology, University Medical Center of the Johannes Gutenberg-University, Langenbeckstr. 1, 55131 Mainz, Germany
3 shared publications - Christian Becker
Department of Dermatology, Johannes Gutenberg-University, Mainz, Germany
2 shared publications Anita Correll
Department of Dermatology, Universitätsmedizin Mainz, Johannes Gutenberg-University, Mainz, Germany
1 shared publication- Anita Correll1 shared publication
- Kerstin Steinbrink
Department of Dermatology, J. Gutenberg‐University, D‐55101 Mainz, Germany
1 shared publication - Susanne A. Hahn
Department of Dermatology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
1 shared publication
Latest Publications
- 1 January 2011
- Vol. 57, 1-12
Immune regulation by dendritic cells and T cells--basic science, diagnostic, and clinical application.
Dendritic cells (DC) are professional antigen-presenting cells defined by their ability to transport incoming infectious signals from the periphery to T cell areas in lymphoid organs and by their unique properties to induce primary T cell activation. As sentinels of immunity DC play a critical role in the initiation of immune responses. Thus, they are key targets in antigen-specific immunotherapeutic strategies for cancer. However, beside this essential immunostimulatory function in the immune system, DC also play an important role in the maintenance of peripheral tolerance. Dependent on subtype and mode of activation, tissue resident immature DC differentiate into immunostimulatory or immunosuppressive antigen-presenting cells with a strong capacity to activate or to inhibit T cell responses, respectively. This review summarizes our current knowledge about the complex interaction between DC and T cells considering both--immunity and tolerance--as well as the possibilities to use this knowledge for development of novel diagnostic and immunotherapeutic strategies to treat immune-imbalanced human diseases such as cancer, allergy, and autoimmunity.
- 1 January 2011
- Vol. 57, 1-12
Immune regulation by dendritic cells and T cells--basic science, diagnostic, and clinical application.
Dendritic cells (DC) are professional antigen-presenting cells defined by their ability to transport incoming infectious signals from the periphery to T cell areas in lymphoid organs and by their unique properties to induce primary T cell activation. As sentinels of immunity DC play a critical role in the initiation of immune responses. Thus, they are key targets in antigen-specific immunotherapeutic strategies for cancer. However, beside this essential immunostimulatory function in the immune system, DC also play an important role in the maintenance of peripheral tolerance. Dependent on subtype and mode of activation, tissue resident immature DC differentiate into immunostimulatory or immunosuppressive antigen-presenting cells with a strong capacity to activate or to inhibit T cell responses, respectively. This review summarizes our current knowledge about the complex interaction between DC and T cells considering both--immunity and tolerance--as well as the possibilities to use this knowledge for development of novel diagnostic and immunotherapeutic strategies to treat immune-imbalanced human diseases such as cancer, allergy, and autoimmunity.
- Open Access
- 21 July 2010
- Published by Wiley in Experimental Dermatology
- Vol. 19 (8) , e213-e221
Increased regulatory T‐cell frequencies in patients with advanced melanoma correlate with a generally impaired T‐cell responsiveness and are restored after dendritic cell‐based vaccination
Please cite this paper as: Increased regulatory T‐cell frequencies in patients with advanced melanoma correlate with a generally impaired T‐cell responsiveness and are restored after dendritic cell‐based vaccination. Experimental Dermatology 2010; 19: e213–e221.Abstract: Naturally occurring CD4+ CD25+ regulatory T‐cell (Treg) activity is assumed to facilitate tumor development and progression. To elucidate the possible role of Tregs in the course of melanoma progression, we analysed the frequency of Tregs in the peripheral blood of patients at melanoma stages I–IV and in patients at melanoma stage IV that underwent dendritic cell (DC)‐based immunotherapy. Using CD25, Foxp3, CD127 and HLA‐DR as Treg associated markers, we observed increased Treg frequencies in patients at the late melanoma stage (stage IV) when compared to healthy donors. Accumulation of Tregs in patients with progressed melanoma correlated with a general reduction of T‐cell responsiveness to the recall antigens tetanus toxoid and tuberculin‐GT. However, DC‐based immunotherapy not only restored antigen‐specific immunity, but also decreased the frequency of Tregs in peripheral blood of patients with melanoma. These findings indicate that tumor progression in patients with melanoma result in general immunosuppression that is associated with Treg expansion in the periphery and can be overcome by DC‐based vaccination.
- 21 July 2010
- Published by Wiley in Experimental Dermatology
- Vol. 19 (8) , e213-e221
Open AccessIncreased regulatory T‐cell frequencies in patients with advanced melanoma correlate with a generally impaired T‐cell responsiveness and are restored after dendritic cell‐based vaccination
Please cite this paper as: Increased regulatory T‐cell frequencies in patients with advanced melanoma correlate with a generally impaired T‐cell responsiveness and are restored after dendritic cell‐based vaccination. Experimental Dermatology 2010; 19: e213–e221.Abstract: Naturally occurring CD4+ CD25+ regulatory T‐cell (Treg) activity is assumed to facilitate tumor development and progression. To elucidate the possible role of Tregs in the course of melanoma progression, we analysed the frequency of Tregs in the peripheral blood of patients at melanoma stages I–IV and in patients at melanoma stage IV that underwent dendritic cell (DC)‐based immunotherapy. Using CD25, Foxp3, CD127 and HLA‐DR as Treg associated markers, we observed increased Treg frequencies in patients at the late melanoma stage (stage IV) when compared to healthy donors. Accumulation of Tregs in patients with progressed melanoma correlated with a general reduction of T‐cell responsiveness to the recall antigens tetanus toxoid and tuberculin‐GT. However, DC‐based immunotherapy not only restored antigen‐specific immunity, but also decreased the frequency of Tregs in peripheral blood of patients with melanoma. These findings indicate that tumor progression in patients with melanoma result in general immunosuppression that is associated with Treg expansion in the periphery and can be overcome by DC‐based vaccination.